Five PLus Year EffIcacy of Endoscopic Sleeve Gastroplasty (ESG) for Sustained WeigHT Loss
Launched by BOSTON SCIENTIFIC CORPORATION · Mar 19, 2025
Trial Information
Current as of April 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the long-term effects of a procedure called Endoscopic Sleeve Gastroplasty (ESG) on weight loss. ESG is a minimally invasive treatment that helps people lose weight and improve related health conditions. The study aims to understand how patients who had this procedure more than five years ago have maintained their weight loss and what their journey has been like since then.
To participate, individuals must be at least 18 years old and have a body mass index (BMI) between 30 and 50, which indicates obesity. Participants should have completed at least one follow-up appointment after their ESG procedure, and they must be willing to attend one more appointment for the study. There are no specific exclusions, so if you meet the age and BMI criteria and have kept up with your follow-up visits, you could be eligible. If you join the study, you can expect to share your experiences and have your progress assessed to help researchers understand the long-term benefits of ESG.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subject is ≥ 18 years of age at the time of the ESG procedure
- • Subject with a BMI between 30 kg/m2 and 50 kg/m2, inclusive, at the time of the primary ESG procedure using Overstitch Endoscopic Suturing System
- • Subject completed follow-up 1-year from the ESG procedure for weight loss management
- • Subject completed or is eligible for follow-up 5-years from the ESG procedure for weight loss management (visit can be collected either retrospectively or prospectively)
- • Subject has returned for a minimum of one annual follow-up at the treating site for weight loss management annually between two and four years from the procedure.
- • Subject is willing to complete one prospective visit (5 year or 5+ year, as appropriate)
- • Subject is able to read, understand, and sign a written Informed Consent Form to participate in the study
- Exclusion Criteria:
- • None
About Boston Scientific Corporation
Boston Scientific Corporation is a global leader in medical device innovation, dedicated to providing solutions that enhance patient care and improve clinical outcomes. With a strong focus on advancing the treatment of various medical conditions, Boston Scientific develops and manufactures a diverse range of products across multiple specialties, including cardiology, urology, and endoscopy. The company is committed to rigorous clinical research and development, ensuring that its devices meet the highest standards of safety and efficacy. Through collaboration with healthcare professionals and ongoing investment in technology and education, Boston Scientific strives to deliver breakthrough therapies that address unmet medical needs and empower patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported